Gene Bridges Licenses Recombineering Technology to Daiichi Sankyo Co., Ltd.

27-Mar-2009 - Germany

Gene Bridges GmbH announced that Daiichi Sankyo Co., Ltd. has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan under the title "Novel DNA cloning Method“, is a valued method for generating targeting vectors or modifying E. coli chromosomes.

“We are very pleased to welcome another major Japanese pharmaceutical company as a licensee of Red/ET,” commented Gary Stevens, CEO of Gene Bridges GmbH. “Recombineering is becoming the technology of choice in DNA engineering and with the help of Daiichi Sankyo Co., Ltd., we expect to gain further acceptance of Red/ET in industry and academia worldwide.”

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?